BioAffinity Stock Surges 61% On Positive CyPath Lung Case Studies

(RTTNews) - bioAffinity Technologies, Inc. (BIAF) rose 61.05 percent to $5.49 on Friday, up $2.08, after the company released three new case studies highlighting the benefits of its CyPath Lung test. The studies showed early detection of lung cancer at Stage 1A and demonstrated how the diagnostic tool helped patients avoid risky invasive procedures. The stock opened at $6.20 and moved between $5.08 and $7.29 during the session, compared with a previous close of $3.41 on the Nasdaq. Trading volume spiked to 88.2 million shares, far above the average of 188,000. The stock now trades within a 52 week range of $3.40 to $67.11.